Insulin resistance negatively affects long-term outcome in non-diabetic patients with coronary artery disease after therapies to reduce atherosclerotic risk factors

Journal of Cardiology

Volumn 62, Issue 6, 2013, Pages 348-353

  Kitta, Yoshinobu ^a   Nakamura, Takamitsu ^a   Uematsu, Manabu ^a   Sugamata, Wataru ^a   Deyama, Juntarou ^a   Fujioka, Daisuke ^a   Saito, Yukio ^a   Kawabata, Kenichi ^a   Obata, Jun ei ^a   Kugiyama, Kiyotaka ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Atherosclerotic risk factors; Cardiovascular disease; Insulin resistance

Indexed keywords

GLUCOSE; INSULIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BRAIN ISCHEMIA; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON DIABETIC PATIENT; PATIENT; PROSPECTIVE STUDY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ATHEROSCLEROTIC RISK FACTORS; CARDIOVASCULAR DISEASE; INSULIN RESISTANCE;

AGED; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84892432157     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.05.006     Document Type: Article

References (32)

1. Reaven G.M. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
2. DeFronzo R.A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
3. Wang H., Hu B., Lu W., Liu F., Feng B. The relationship of angiographically defined coronary artery disease with insulin sensitivity and secretion in subjects with different glucose tolerance. J Cardiol 2012, 61:367-371.
4. Hedblad B., Nilsson P., Engström G., Berglund G., Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002, 19:470-475.
5. Ausk K.J., Boyko E.J., Ioannou G.N. Insulin resistance predicts mortality in nondiabetic individuals in the US. Diabetes Care 2007, 33:1179-1185.
6. Gibbons R.J., Abrams J., Chatterjee K., Daley J., Deedwania P.C., Douglas J.S., Ferguson T.B., Fihn S.D., Fraker T.D., Gardin J.M., O'Rourke R.A., Pastemak R.C., William S.V. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003, 41:156-168.
7. Smith S.C., Blair S.N., Bonow R.O., Brass L.M., Cerqueira M.D., Dracup K., Fuster V., Gotto A., Grundy S.M., Miller N.H., Jacobs A., Jones D., Krauss R.M., Mosca L., Ockene I., et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001, 38:1581-1583.
8. Reaven G., Tsao P.S. Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease. J Am Coll Cardiol 2003, 41:1044-1047.
9. Al-Mahmood A.K., Ismail A.A., Rashid F.A., Azwany Y.N., Singh R., Gill G. Effect of therapeutic lifestyle changes on insulin sensitivity of non-obese hyperlipidemic subjects: preliminary report. J Atheroscler Thromb 2007, 14:122-127.
10. Sakamoto A., Ishizaka Y., Toda E., Nagai R., Koike K., Yamakado M., Ishizaka N. Impact of changes in obesity parameters on glucose metabolism and insulin resistance over a once-year period. J Atheroscler Thromb 2010, 17:1246-1255.
11. Mason C., Foster-Schubert K., Imayama I., Kong A., Xiao L., Bain C., Campbell K.L., Wang C.Y., Duggan C.R., Ulrich C.M., Alfano C.M., Blackburn G.L., McTieman A. Dietary weight loss and exercise effects on insulin resistance in postmenopausal women. Am J Prev Med 2011, 41:366-375.
12. Hirano M., Nakamura T., Kitta Y., Yano T., Kobayashi T., Sano K., Fujioka D., Saito Y., Kodama Y., Kawabata K., Nakamura K., Obata J.E., Kugiyama K. Rapid improvement of carotid plaque echogenicity within 1 month of pioglitazone treatment in patients with acute coronary syndrome. Atherosclerosis 2009, 203:483-488.
13. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program. Effects of lifestyle intervention and metformin. Diabetes 2005, 54:2404-2414. The Diabetes Prevention Program Research Group.
14. Malik J., Melenovsky V., Wichterle D., Haas T., Simek J., Ceska R., Hradec J. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate vs atorvastatin trial-FAT). Cardiovasc Res 2001, 52:290-298.
15. Ichikawa Y. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 2007, 46:1331-1336.
16. Nakamura T., Kodama Y., Takano H., Umetani K., Fujioka D., Saito Y., Kawabata K., Obata J.E., Kitta Y., Kobayashi T., Mende A., Kugiyama K. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 2007, 193:449-451.
17. Hiramitsu S., Miyagishima K., Ishii J., Matsui S., Naruse H., Shiino K., Kitagawa F., Ozaki Y. The effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 2012, 60:395-400.
18. Hanley A.J., Williams K., Stern M.P., Haffner S.M. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease. Diabetes Care 2002, 25:1177-1184.
19. Isomaa B., Almgren P., Tuomi T., Forsen B., Lahti K., Nissen M., Taskinen M.R., Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetic Care 2001, 24:683-689.
20. Hedblad B., Nilsson P., Engstorm G., Berglund G., Janzon L. Insulin resistance in non-diabetic subjects is associated with incidence of myocardial infarction and death. Diabet Med 2002, 19:470-475.
21. Bonora E., Kiechi S., Willeit J., Oberhollenzer F., Egger G., Meigs J.B., Bonadonna R.C., Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population. Diabetes Care 2007, 30:318-324.
22. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino R.B., Wilson P.W. Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes Care 2005, 54:3252-3257.
23. Meigs J.B., Rutter M.K., Sullivan L.M., Fox C.S., D'Agostino R.B., Wilson P.W. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007, 30:1219-1225.
24. Katayama T., Ueba H., Tsuboi K., Kubo N., Yasu T., Kuroki M., Saito M., Momomura S., Kawakami M. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J 2007, 153:762e1-762e7.
25. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26:S5-S20. Expert Committee on the Diagnosis, Classification of Diabetes Mellitus.
26. The Examination Committee of Criteria for Obesity Disease in Japan, Japan Society for the Study of Obesity New criteria for obesity disease in Japan. Circ J 2002, 66:987-992.
27. Kugiyama K., Doi H., Motoyama T., Soejima H., Misumi K., Kawano Nakagawa O., Yoshimura M., Ogawa H., Matsumura T., Sugiyama S., Nakano T., Nakajima K., Yasue H. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998, 97:2519-2526.
28. Haffner S.M., Miettinen H., Stern M.P. The homeostasis model in the San Antonio Heart study. Diabetes Care 1997, 20:1087-1092.
29. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil A.W. 10-Year follow-up of intensive glucose control on type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
30. Schramm T.K., Gislason G.H., Vaag A., Rasmusen J.N., Folke F., Hansen M.L., Fosbol E.L., Kober L., Norgaard M.L., Madsen M., Hansen P.R., Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart 2011, 32:1900-1908.
31. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
32. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-E223.